TB-500 (Thymosin Beta-4 Fragment) Dosage Protocol

TB-500 is a synthetic fragment of Thymosin Beta-4, a regenerative peptide found in nearly all human cell types. It is studied for tissue repair, wound healing, and cardiac regeneration.

Dosing & Reconstitution Guide

Route: Subcutaneous  |  Frequency: Once daily  |  Half-life: ~60 minutes

Standard Approach (3 mL = 3.33 mg/mL)

Reconstituting with 3 mL bacteriostatic water produces a concentration of 3.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.

Reconstitution Steps

1. Wipe the vial stopper and BAC water vial with alcohol; let dry.
2. Draw 3 mL of bacteriostatic water into a sterile syringe.
3. Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
4. Gently swirl until fully dissolved. Do not shake.
5. Label with reconstitution date. Refrigerate at 2–8°C; use within 30 days.

Supplies Needed

Estimates for an 8-week and 12-week cycle at 750 mcg per dose, once daily (7 doses/week).

Protocol Overview

TB-500 protocols use gradual daily titration to a steady-state dose. Total weekly dose averages ~5 mg, consistent with the most-cited research protocols.

The peptide is particularly studied for connective-tissue injuries (tendons, ligaments, fascia) and in stacked protocols with BPC-157 (Wolverine Blend) where the two work via complementary mechanisms.

Cycle length: 8–12-week daily protocol is the standard pattern. Some users extend to 16 weeks for chronic injury support.

Note on athletic competition: TB-500 is on the WADA prohibited list. Out-of-competition detection windows exist.

Dosing Protocol

Daily titration approach (subcutaneous):

• Weeks 1–2: 500 mcg/day (15 units at 3.33 mg/mL).
• Weeks 3–4: 600 mcg/day.
• Weeks 5–8: 750 mcg/day.
• Weeks 9–12 (target): 1000 mcg (1 mg) /day.

Cycle structure: 8–12 weeks daily → 4-week break. Extend to 16 weeks if research goals require.

Weekly total: ~3.5–7 mg/week (averages 5 mg/week across the cycle).

Stacking: Wolverine Blend (BPC-157 + TB-500) is the most common research protocol — each peptide hits different aspects of soft-tissue repair.

Timing: Once per day at a consistent time; rotate injection sites.

Storage Instructions

Important Notes

How This Works

TB-500 is a synthetic fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein found in virtually every human cell and concentrated in platelets and wound fluid. The active TB-500 region binds G-actin and regulates cytoskeletal organization and cell motility.

It promotes endothelial cell migration, accelerates wound closure, supports cardiomyocyte recovery after infarction, reduces fibrosis, and modulates inflammatory cytokine release. The peptide also up-regulates laminin-5 and integrin-linked kinase, both involved in cell-matrix adhesion during repair.

Potential Benefits & Side Effects

Potential Benefits

• Accelerated wound closure and reduced scarring in rodent models.
• Cardioprotective effects post-infarction in mouse models.
• Promotes hair regrowth in animal alopecia models.
• Anti-inflammatory action via NF-κB downregulation.
• Synergy with BPC-157 in connective-tissue protocols.

Side Effect Profile

• Generally well-tolerated.
• Mild injection-site soreness possible.
• Transient fatigue during first 1–2 weeks of loading.
• Theoretical pro-angiogenic concerns with occult malignancy.

Lifestyle Factors

• Pair with physical therapy for tendon/ligament work.
• Adequate protein (1.2–1.6 g/kg/day).
• Vitamin C, zinc, copper sufficiency support wound healing.
• Avoid chronic NSAIDs during active connective-tissue repair.

Injection Technique

• Subcutaneous — abdomen, thigh, or near the injury site.
• Rotate sites with each dose during loading phase.
• 90° angle with short insulin needle.